Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Junji Tsurutani et al.|New England Journal of Medicine|2022Cited by 2.5k
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L. Mayer, Michael Gnant, Amylou C. Dueck et al.|The Lancet Oncology|2021Cited by 255
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Cristina Saura et al.|The Lancet Oncology|2019Cited by 199